Stillwater Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-307,641
| Closed | -$15.8M | – | 70 |
|
|
2022
Q4 | $15.8M | Sell |
307,641
-5,829
| -2% | -$279K | 3.33% | 9 |
|
|
2022
Q3 | $13.7M | Sell |
313,470
-17,990
| -5% | -$874K | 3.13% | 11 |
|
|
2022
Q2 | $17.4M | Buy |
331,460
+1,624
| +0.5% | +$82.8K | 3.23% | 9 |
|
|
2022
Q1 | $17.1M | Sell |
329,836
-3,710
| -1% | -$192K | 2.74% | 12 |
|
|
2021
Q4 | $19.7M | Sell |
333,546
-2,456
| -0.7% | -$122K | 3% | 12 |
|
|
2021
Q3 | $14.5M | Sell |
336,002
-2,010
| -0.6% | -$89K | 2.38% | 17 |
|
|
2021
Q2 | $13.2M | Buy |
338,012
+4,064
| +1% | +$158K | 2.19% | 21 |
|
|
2021
Q1 | $12.1M | Buy |
333,948
+1,721
| +0.5% | +$61.1K | 2.19% | 23 |
|
|
2020
Q4 | $12.2M | Sell |
332,227
-20,525
| -6% | -$753K | 2.34% | 20 |
|
|
2020
Q3 | $12.3M | Sell |
352,752
-420
| -0.1% | -$14.7K | 2.68% | 16 |
|
|
2020
Q2 | $11M | Buy |
353,172
+4,204
| +1% | +$143K | 2.64% | 17 |
|
|
2020
Q1 | $10.8M | Sell |
348,968
-271
| -0.1% | -$9.23K | 3.18% | 8 |
|
|
2019
Q4 | $13M | Buy |
349,239
+4,771
| +1% | +$170K | 2.94% | 10 |
|
|
2019
Q3 | $11.7M | Sell |
344,468
-2,933
| -0.8% | -$107K | 2.98% | 11 |
|
|
2019
Q2 | $14.3M | Sell |
347,401
-32,694
| -9% | -$1.3M | 3.53% | 7 |
|
|
2019
Q1 | $15.3M | Sell |
380,095
-5,207
| -1% | -$209K | 3.34% | 7 |
|
|
2018
Q4 | $16M | Sell |
385,302
-10,739
| -3% | -$446K | 3.98% | 5 |
|
|
2018
Q3 | $16.6M | Buy |
396,041
+3,018
| +0.8% | +$116K | 3.44% | 7 |
|
|
2018
Q2 | $13.5M | Sell |
393,023
-5,927
| -1% | -$203K | 3.23% | 8 |
|
|
2018
Q1 | $13.4M | Sell |
398,950
-143
| -0% | -$4.92K | 3.23% | 7 |
|
|
2017
Q4 | $13.7M | Sell |
399,093
-1,901
| -0.5% | -$64.8K | 3.23% | 7 |
|
|
2017
Q3 | $13.6M | Buy |
400,994
+8,768
| +2% | +$282K | 3.52% | 5 |
|
|
2017
Q2 | $12.5M | Buy |
392,226
+6,193
| +2% | +$195K | 3.17% | 10 |
|
|
2017
Q1 | $12.5M | Sell |
386,033
-4,615
| -1% | -$146K | 3.33% | 6 |
|
|
2016
Q4 | $12M | Buy |
390,648
+1,847
| +0.5% | +$56.4K | 3.22% | 10 |
|
|
2016
Q3 | $12.5M | Sell |
388,801
-4,590
| -1% | -$153K | 3.64% | 4 |
|
|
2016
Q2 | $13.1M | Sell |
393,391
-1,183
| -0.3% | -$37.8K | 3.92% | 2 |
|
|
2016
Q1 | $11.1M | Sell |
394,574
-1,960
| -0.5% | -$56K | 3.28% | 10 |
|
|
2015
Q4 | $12.1M | Buy |
396,534
+87
| +0% | +$2.74K | 3.72% | 6 |
|
|
2015
Q3 | $11.8M | Sell |
396,447
-2,231
| -0.6% | -$71.5K | 4.03% | 3 |
|
|
2015
Q2 | $12.7M | Buy |
398,678
+3,801
| +1% | +$124K | 3.67% | 4 |
|
|
2015
Q1 | $13M | Buy |
394,877
+7,491
| +2% | +$238K | 3.96% | 2 |
|
|
2014
Q4 | $11.4M | Buy |
387,386
+47,008
| +14% | +$1.35M | 3.44% | 6 |
|
|
2014
Q3 | $9.55M | Buy |
340,378
+4,605
| +1% | +$129K | 3.19% | 10 |
|
|
2014
Q2 | $9.46M | Buy |
335,773
+5,208
| +2% | +$148K | 3.21% | 14 |
|
|
2014
Q1 | $10.1M | Buy |
330,565
+3,082
| +0.9% | +$91.9K | 3.66% | 3 |
|
|
2013
Q4 | $9.52M | Buy |
327,483
+75,920
| +30% | +$2.21M | 3.69% | 7 |
|
|
2013
Q3 | $6.86M | Sell |
251,563
-5,824
| -2% | -$158K | 4.05% | 3 |
|
|
2013
Q2 | $6.84M | Buy |
+257,387
| New | +$7.11M | 4.23% | 2 |
|
Other funds holding PFE
Stillwater Capital Advisors's PFE Position: Q1 2023 in Review
Stillwater Capital Advisors sold out of Pfizer (PFE) in Q1 2023, closing a stake of 307,641 shares — an estimated $15.8M sold.
Stillwater Capital Advisors first reported a position in PFE in Q2 2013 and held it in 39 quarters. The position peaked at $19.7M in Q4 2021. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.
- Stillwater Capital Advisors reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
- Stillwater Capital Advisors sold 307,641 Pfizer shares in Q1 2023, an estimated $15.8M.
- Stillwater Capital Advisors first reported a position in Pfizer in Q2 2013 and held it in 39 quarters.
- Stillwater Capital Advisors's Pfizer position peaked at $19.7M in Q4 2021.
- 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.
Based on Stillwater Capital Advisors's 13F filing for Q1 2023, filed 1 May 2023.